| 3.65 0.09 (2.53%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.65 | 1-year : | 4.99 |
| Resists | First : | 3.98 | Second : | 4.28 |
| Pivot price | 3.79  |
|||
| Supports | First : | 3.5 | Second : | 2.92 |
| MAs | MA(5) : | 3.59 |
MA(20) : | 3.87 |
| MA(100) : | 3.56 |
MA(250) : | 5.44 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 8.6 |
D(3) : | 5.2 |
| RSI | RSI(14): 45.2 |
|||
| 52-week | High : | 11.84 | Low : | 2.7 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NURO ] has closed above bottom band by 30.9%. Bollinger Bands are 17.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.81 - 3.83 | 3.83 - 3.85 |
| Low: | 3.51 - 3.53 | 3.53 - 3.55 |
| Close: | 3.62 - 3.65 | 3.65 - 3.68 |
NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Thu, 18 Apr 2024
NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com - Defense World
Tue, 12 Mar 2024
Echo Lake Capital urges Neurometrix to dismiss CEO - Investing.com
Mon, 04 Mar 2024
Echo Lake Capital urges Neurometrix to liquidate By Investing.com - Investing.com
Mon, 28 Aug 2023
Is NeuroMetrix (NURO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap - Yahoo Finance
Mon, 23 Jan 2023
NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral ... - GlobeNewswire
Wed, 12 Jan 2022
Best Penny Stocks To Buy Now? 4 On Webull With Bullish User Ratings - Penny Stocks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 16 (%) |
| Held by Institutions | 5.6 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 43 (K) |
| EPS | -6.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.18 |
| Profit Margin | -110.7 % |
| Operating Margin | -141 % |
| Return on Assets (ttm) | -19.4 % |
| Return on Equity (ttm) | -30.1 % |
| Qtrly Rev. Growth | -28.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.96 |
| EBITDA (p.s.) | -3.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.59 |
| PEG Ratio | 0 |
| Price to Book value | 0.27 |
| Price to Sales | 1.23 |
| Price to Cash Flow | -1.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|